Skip to Main Content

Paper Details

Patient derived organoids to model rare prostate cancer phenotypes.
Nat Commun
217
2018
EZH2, Neuroendocrine prostate cancer, Patient, Patient derived organoids, cancer, castration-resistant prostate cancer, metastatic, neuroendocrine prostate cancer, organoids, patient, patients, prostate cancer, rare tumors, tumor, tumor organoids, tumors
Author NameAffiliation
Loredana Puca
Loredana PucaMeyer Cancer Center
Loredana PucaEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Rohan BarejaEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Rohan BarejaInstitute for Computational Biomedicine
Davide PrandiCenter for Integrative Biology, University of Trento
Davide PrandiCenter for Integrative Biology, University of Trento
Michael Sigouros
Myriam Kossai
Joanna CyrtaEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Verena SailerEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Aram VosoughiEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Chantal PauliEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Cynthia CheungEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Terra J McNaryEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Scott T Tagawa
Scott T TagawaMeyer Cancer Center
David M Nanus
David M NanusMeyer Cancer Center
Juan Miguel MosqueraMeyer Cancer Center
Juan Miguel Mosquera
Juan Miguel MosqueraEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Juan Miguel MosqueraMeyer Cancer Center
Juan Miguel MosqueraEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Juan Miguel Mosquera
Charles L SawyersMemorial Sloan Kettering Cancer Center
Yu ChenMemorial Sloan Kettering Cancer Center
Giorgio Inghirami
Rema RaoEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Olivier ElementoMeyer Cancer Center
Olivier ElementoInstitute for Computational Biomedicine
Olivier ElementoEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Olivier ElementoMeyer Cancer Center
Olivier ElementoEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Olivier ElementoInstitute for Computational Biomedicine
Andrea SbonerEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Andrea SbonerInstitute for Computational Biomedicine
Andrea SbonerEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Andrea SbonerInstitute for Computational Biomedicine
Francesca DemichelisEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Francesca DemichelisCenter for Integrative Biology, University of Trento
Francesca DemichelisEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Francesca DemichelisCenter for Integrative Biology, University of Trento
Mark A RubinEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Mark A Rubin
Mark A RubinEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
Mark A Rubin
Himisha Beltran
Himisha BeltranMeyer Cancer Center
Himisha BeltranEnglander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
  • 1 - 50

Datasets